Call for More Study on Vitamin C and Cancer
Posted on: Monday, 24 April 2006, 12:00 CDT
WICHITA, Kan., April 24 /PRNewswire/ -- In a Canadian Medical Association Journal (CMAJ) article, researchers at the National Institutes of Health and the Center for the Improvement of Human Functioning International (CIHFI) reported on 3 well-documented cases of advanced cancer, confirmed by histopathologic review, where patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. Clinical details of each case were assessed in accordance with National Cancer Institute (NCI) Best Case Series guidelines, and the researchers found that the case reports indicate that the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed.
Patients whose case studies were reviewed were treated by Hugh Riordan, M.D., at CIHFI in Wichita, Kansas. http://www.brightspot.org/ . Each patient was treated for a different type of cancer: renal cell carcinoma metastasized to the lungs, stage II bladder cancer and diffuse large B-cell lymphoma. The CMAJ article was dedicated to the memory of one of the co-authors, Dr. Hugh Riordan, who died suddenly during the writing of the manuscript.
"We are pleased to see that our long-term collaboration with Dr. Levine and Dr. Padayatty at NIH has allowed for higher visibility of the potential of vitamin C for people who suffer from cancer," stated Dr. Neil Riordan, Director of Research at CIHFI.
Riordan continued, "We are encouraged that the work of NIH and CIHFI is being published and recognized. There has been no financial incentive for pharmaceutical companies to study the effects of vitamin C on cancer -- so the only remaining research funding sources are government and private charities funded by generous, forward-thinking benefactors."
Doctors and researchers at CIHFI have been involved in the study of vitamin C and cancer at the bench level and clinically over the past 20 years. CIHFI and its research division, the Bio-Communications Research Institute, have published scientific articles on vitamin C's beneficial effects for cancer patients from the bench level to clinical reports. Most recently they, along with collaborators at the University of Puerto Rico, published the first clinical safety study of high-dose intravenous vitamin C in cancer patients. Funding for this research has been provided by individuals, the Lincoln Family Foundation, Bob and Marge Page, the Flossie West Trust Foundation, and members of the Garvey and Marietta families.
Bio-Communications Research Institute
CONTACT: Renee Olmstead of Bio-Communications Research Institute,+1-316-204-0000
Web site: http://www.brightspot.org/
Source: PRNewswire
Related Articles
- Prostate Cancer Translational Research in Europe Meeting
- Monterey Institute of International Studies Sees 10x Network Performance Gains With PWT-IT Solution's 3Com Powered Data Network Overhaul
- H. Lee Moffitt Cancer Center and Inovio Biomedical to Unveil Pioneering Clinical Study Data of Plasmid DNA Delivery Using Electroporation
- Institute for the Study of Aging and Elan Pharmaceuticals Announce Winners of New Alzheimer's Disease Drug Discovery Award Program
- Resolution Health Sponsors NY Business Group on Health Event Featuring Horizon Healthcare Services Patient Communications Program; Thursday, December 8, 2005, 8-10 AM
- Missing Protein May Hold Lung Cancer Key -Research
- Genentech Stops Enrolling Patients in Study
- Tai Chi Helps Women Recover From Breast Cancer Surgery: Researcher
- Institute for the Study of Aging Receives Generous Donation From Elan Pharmaceuticals to Create a New Alzheimer's Disease Research Program
- Spinnaker Networks Provides Storage Power for Brain Cell and Systems Research at the Salk Institute
 |
 |
User Comments (0)
RSS Feeds